Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 175

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 175
---
.0 each of the representations and warranties of TELI set forth in Section 3shall be true and correct in all respects at and as of the Closing Date, (other than representations or warranties that address matters only as of a certain date, which shall be true and correct as of such date), except where the failure of such representations and warranties to be true and correct, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect on TELI;

6.3.1 each of the covenants and obligations of TELI to be performed at or before the Effective Time pursuant to the terms of this Agreement, including, without limitation, the covenants set forth in Section 5.2, shall have been duly performed in all material respects at or before the Effective Time;

6.3.2 TELI shall not have suffered a Material Adverse Effect after the date hereof; and

6.3.3 Certain major shareholders of TELI (including Bayshore Trust and related parties, the “ Contributing Shareholders”) shall have committed to contribute to Company assets and/or cash (or any combination thereof) totaling $5,000,000 (the “ Cash Contribution”), with $1,000,000 due at Closing, $2,000,000 due upon acceptance by the U.S. Food and Drug Administration (“ FDA”) of the applicable Investigational New Drug application (“ IND”), and $2,000,000 due upon initiation of Phase 1 or 2 clinical trial. In the event any milestone contribution is not funded within three (3) months of the applicable milestone date, the corresponding shares shall be automatically canceled and permanently revert to the Company’s treasury, without adjustment to the exchange ratio or other terms of the Agreement.

<div align='center'>Article VII Termination</div>

7.1 Termination. Notwithstanding anything to the contrary in this Agreement, this Agreement may be terminated and the Merger may be abandoned at any time prior to the Effective Time:

7.1.0 By mutual written consent of the Company and TELI;

7.1.1 By either the Company or TELI, upon delivery of written notice to the other, if the Closing shall not have occurred on or before December 31, 2025 (the “ Termination Date”); provided, however, that neither the Company nor TELI will be entitled to terminate this Agreement under this Section ‎7.1.1if such Person